SGLT2 Inhibitors in Stage 5 Chronic Kidney Disease: A Systematic Review and Meta-analysis of Cardiovascular and Kidney Outcomes

**Background:** Evidence supporting sodium-glucose cotransporter-2 (SGLT2) inhibitor use in stage 5 chronic kidney disease (CKD) remains limited because major randomized trials have largely excluded this population. We evaluated associations between SGLT2 inhibitor use and cardiovascular and kidney outcomes in patients with stage 5 CKD. **Methods:** We systematically searched PubMed, Scopus, Cochrane CENTRAL, and Google Scholar through April 10, 2026. Studies comparing SGLT2 inhibitors with nonuse or other glucose-lowering therapies were eligible. Hazard ratios (HRs) were pooled using random-effects models, and risk of bias was assessed using ROBINS-I. Certainty of evidence was assessed using GRADE. **Results:** Five observational cohorts met inclusion criteria, of which three contributed to the meta-analysis, comprising 57,156 participants, including 28,559 SGLT2 inhibitor users. SGLT2 inhibitor use was associated with fewer heart failure hospitalizations (HR 0.78; 95% CI 0.72-0.85) and acute myocardial infarctions (HR 0.64; 95% CI 0.56-0.72). Associations with all-cause mortality (HR 0.84; 95% CI 0.58-1.21) and dialysis initiation (HR 0.63; 95% CI 0.30-1.33) were not statistically significant. In analyses restricted to treatment-initiation cohorts, the association with fewer heart failure hospitalizations persisted, whereas the myocardial infarction association was no longer significant. Certainty of evidence was low or very low across outcomes. **Conclusions:** Observational evidence suggests potential cardiovascular benefits of SGLT2 inhibitors in stage 5 CKD, particularly fewer heart failure hospitalizations. Effects on mortality, dialysis initiation, and myocardial infarction remain uncertain. Dedicated randomized trials are needed to establish efficacy and safety in this population.

Authors

Publication Details

Journal
medRxiv
Published
2026-11-13
DOI
https://doi.org/10.64898/2026.11.12.26367903
Primary Topic
Diabetes Treatment and Management
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

SGLT2 Inhibitors in Stage 5 Chronic Kidney Disease: A Systematic Review and Meta-analysis of Cardiovascular and Kidney Outcomes

Muhammad Abid Owais, Ubaid ur Rehman, Hafiz M. Ahmed
3 links
medRxiv
Diabetes Treatment and Management
preprint

SGLT2 Inhibitors in Stage 5 Chronic Kidney Disease: A Systematic Review and Meta-analysis of Cardiovascular and Kidney Outcomes

Muhammad Abid Owais, Ubaid ur Rehman, Hafiz M. Ahmed
preprint en

Abstract

**Background:** Evidence supporting sodium-glucose cotransporter-2 (SGLT2) inhibitor use in stage 5 chronic kidney disease (CKD) remains limited because major randomized trials have largely excluded this population. We evaluated associations between SGLT2 inhibitor use and cardiovascular and kidney outcomes in patients with stage 5 CKD. **Methods:** We systematically searched PubMed, Scopus, Cochrane CENTRAL, and Google Scholar through April 10, 2026. Studies comparing SGLT2 inhibitors with nonuse or other glucose-lowering therapies were eligible. Hazard ratios (HRs) were pooled using random-effects models, and risk of bias was assessed using ROBINS-I. Certainty of evidence was assessed using GRADE. **Results:** Five observational cohorts met inclusion criteria, of which three contributed to the meta-analysis, comprising 57,156 participants, including 28,559 SGLT2 inhibitor users. SGLT2 inhibitor use was associated with fewer heart failure hospitalizations (HR 0.78; 95% CI 0.72-0.85) and acute myocardial infarctions (HR 0.64; 95% CI 0.56-0.72). Associations with all-cause mortality (HR 0.84; 95% CI 0.58-1.21) and dialysis initiation (HR 0.63; 95% CI 0.30-1.33) were not statistically significant. In analyses restricted to treatment-initiation cohorts, the association with fewer heart failure hospitalizations persisted, whereas the myocardial infarction association was no longer significant. Certainty of evidence was low or very low across outcomes. **Conclusions:** Observational evidence suggests potential cardiovascular benefits of SGLT2 inhibitors in stage 5 CKD, particularly fewer heart failure hospitalizations. Effects on mortality, dialysis initiation, and myocardial infarction remain uncertain. Dedicated randomized trials are needed to establish efficacy and safety in this population.

medRxiv
Good health and well-being
Diabetes Treatment and Management
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon